BioInvent International AB (publ) BINV
Updated: 11 Jun 2026
No signal published yet
We already track BioInvent International and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.
Email when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Temporary check — not Firelda's published signal.
General analysis — not personal advice.
Want to follow BioInvent International AB (publ)? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow BioInvent International free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Recent News
On June 11, 2026, the company announced positive clinical data for its candidates BI-1206 and BI-1808 at the EHA Congress in Stockholm. The results included an 83% response rate for the BI-1206 triplet combination in patients with relapsed/refractory non-Hodgkin's lymphoma.
What Firelda Watch includes for BioInvent International AB (publ)
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — a short weekly roundup
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Want to follow BioInvent International AB (publ)? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow BioInvent International free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more